女性最常见的癌症之一是乳腺癌。尽管乳腺癌的治疗取得了显著进步，但该疾病仍然是妇女死亡的主要原因之一，也是一个重大公共卫生挑战。化学治疗的治疗效果受到化疗药物抗药性和毒性的阻碍。纳米脂质药物传递系统具有可控的药物释放、纳米尺寸和靶向特定部位的特点。乳腺癌治疗包括手术、化学治疗和放射治疗。尽管如此，目前没有一种针对该疾病的单一治疗方法是有效的，因为乳腺癌干细胞转移和化疗抗药性。因此，使用纳米载体系统以靶向乳腺癌干细胞是必要的。本文探讨了乳腺癌治疗方案，包括化疗等现代治疗方法，以及一些突破性的治疗选择，强调了载药脂质纳米载体（如纳米乳化液（NE）、固体脂质纳米颗粒（SLNs）、纳米结构脂质载体（NLCs）和脂质体）在其中的作用，并且它们的研究表明，它们可以限制癌细胞生长，降低复发风险，并最小化化疗后的转移。本文还探讨了已获FDA批准的基于脂质的纳米载体、商业可用的配方和用于进一步研究的基于配体的配方。

One of the most common cancers that occur in females is breast cancer. Despite the significant leaps and bounds that have been made in treatment of breast cancer, the disease remains one of the leading causes of death among women and a major public health challenge. The therapeutic efficacy of chemotherapeutics is hindered by chemoresistance and toxicity. Nano-based lipid drug delivery systems offer controlled drug release, nanometric size, and site-specific targeting. Breast cancer treatment includes surgery, chemotherapy, and radiotherapy. Despite this, no single method of treatment for the condition is currently effective due to cancer stem cell metastasis and chemo-resistance. Therefore, the employment of nanocarrier systems is necessary in order to target breast cancer stem cells. This article addresses breast cancer treatment options, including modern treatment procedures such as chemotherapy, etc., and some innovative therapeutic options highlighting the role of lipidic nanocarriers loaded with chemotherapeutic drugs such as nanoemulsion (NE), solid-lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and liposomes, and their investigations have demonstrated that they can limit cancer cell growth, reduce the risk of recurrence, as well as minimize post-chemotherapy metastasis. This article also explores FDA-approved lipid-based nanocarriers, commercially available formulations, and ligand-based formulations that are being considered for further research.